enGene Holdings Inc. (ENGN) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.49
↓-73% vs avg
5yr avg: 1.82
30Y Low1.4·High2.2
ROE
↓
-53.3%
-20% vs avg
5yr avg: -44.6%
30Y Low-100%·High-18%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ENGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
enGene Holdings Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $83M | $369M | $395M | — | — | — |
| Enterprise Value | $65M | $350M | $247M | — | — | — |
| P/E Ratio → | -0.71 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.49 | 2.20 | 1.45 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ENGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
ENGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -53.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -53.3% | -53.3% | -32.0% | -100.0% | -19.2% | -18.4% |
| ROA | -44.0% | -44.0% | -27.7% | -91.2% | -18.6% | -17.8% |
| ROIC | -67.4% | -67.4% | -74.5% | -30.6% | -11.5% | — |
| ROCE | -50.7% | -50.7% | -32.9% | -24.5% | -14.8% | -12.1% |
ENGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $50M exceeds total debt of $32M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.09 | 0.13 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.11 | -0.54 | -0.99 | -0.00 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -38.18 | -38.18 | -18.71 | -19.17 | -16.17 | -3.67 |
Net cash position: cash ($50M) exceeds total debt ($32M)
ENGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
enGene Holdings Inc.'s current ratio of 6.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.25x to 6.30x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 6.30 | 6.30 | 16.87 | 16.25 | 0.57 | 4.79 |
| Quick Ratio | 6.30 | 6.30 | 16.87 | 16.25 | 0.57 | 4.79 |
| Cash Ratio | 6.06 | 6.06 | 16.26 | 15.52 | 0.35 | 3.27 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
ENGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
enGene Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $51M | $45M | $24M | $16M | $16M |
Peer Comparison
Compare ENGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ENGNYou | $83M | -0.7 | — | — | — | — | -53.3% | -67.4% | — |
 RCKT | $300M | -1.4 | — | — | — | — | -60.3% | -62.4% | — |
 KRYS | $9B | 46.5 | 52.9 | 49.6 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 JANX | $827M | -7.4 | — | — | 79.7% | -1576.7% | -11.5% | -15.3% | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $245M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -7.7 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -35.8 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ILMN | $24B | 29.5 | 22.6 | 26.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
What if you invested $1,000 in ENGN 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ENGN be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ENGN Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationENGN vs RCKT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Rocket Pharmaceuticals, Inc..
Compare NowENGN — Frequently Asked Questions
Quick answers to the most common questions about buying ENGN stock.
What is enGene Holdings Inc.'s P/E ratio?
enGene Holdings Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
What is enGene Holdings Inc.'s ROE?
enGene Holdings Inc.'s return on equity (ROE) is -53.3%. The historical average is -44.6%.
Is ENGN stock overvalued?
Based on historical data, enGene Holdings Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.